Far From Certican: Novartis Hopes REMS Will Tip Balance For Kidney Transplant Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's cardio-renal committee will weigh whether a communication-focused risk management plan can assuage concerns about renal toxicity and slow wound healing.
You may also be interested in...
Endpoints For Kidney Transplant Drugs Getting FDA Attention
The agency will conduct a two-day workshop in September to hear from health care providers, academia and industry on potential clinical or surrogate endpoints and biomarkers for clinical trials of drugs for kidney transplant patients.
Panel Recommends Novartis' Kidney Transplant Drug Certican
Taking the panel's previous advice to demonstrate everolimus' efficacy with lower doses of cyclosporine is what gained the committee endorsement Dec. 7.
Panel Recommends Novartis' Kidney Transplant Drug Certican
Taking the panel's previous advice to demonstrate everolimus' efficacy with lower doses of cyclosporine is what gained the committee endorsement Dec. 7.